Viewing Study NCT00695903

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:19 PM
Ignite Modification Date: 2026-06-01 @ 5:58 PM
Study NCT ID: NCT00695903
Status: TERMINATED
Last Update Posted: 2018-12-24
First Post: 2008-06-10
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia
Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Endocarditis, Bacterial View
None Infective Endocarditis View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Gram-positive bacterial infections View
None Staph Aureus View
None Bacteremia View
None MRSA View
None Infective Endocarditis View
None Right-sided Infective endocarditis View
None SABIE View
None SAIE View
None RIE View